SubsidieMeestersRadically New Cancer Therapy Based on Advances in Nanotechnology and Photonics for Simultaneous Imaging and Treatment of Solid Tumours
ScanNanoTreat aims to revolutionize cancer treatment by integrating advanced imaging and therapy technologies to improve patient outcomes and reduce costs, targeting clinical trials by 2027.
Projectdetails
Introduction
Cancer treatment is a significant healthcare challenge, costing Europe up to 199 billion annually. The burden will grow substantially, with a projected 60% increase in cancer cases from 2018 to 2040.
Project Overview
To address these challenges, the ScanNanoTreat consortium, consisting of Claude Bernard Lyon 1 University, Maastricht University, Guerbet, Philips, and Inlecom Commercial Pathways, is developing a revolutionary theranostic approach combining advanced photonics and nanotechnology.
Innovative System
The innovative system integrates:
- Spectral Photon Counting Computed Tomography (SPCCT)
- X-ray-activated Photodynamic Therapy (X-PDT) using gadolinium-based nanoprobes.
This approach enables simultaneous imaging and treatment of solid tumours, with an initial focus on breast and pancreatic cancers.
Benefits of the Technology
By leveraging low-energy X-rays and optimized nanoprobes, ScanNanoTreat aims to:
- Reduce radiation doses by over 30% compared to conventional radiotherapy.
- Radically shorten the diagnosis-treatment cycle.
- Improve prognosis and better patient outcomes.
- Achieve up to a 40% reduction in cancer treatment costs.
Market Potential
If successfully deployed, ScanNanoTreat could revolutionize the European theranostic market, aiming to capture 10-17% of the projected 493 million market by 2032, suggesting a potential market size of 35-60 million by 2035.
Development Timeline
The project will advance the technology from TRL 3 to TRL 5, preparing for clinical trials by 2027 and potential market entry by 2035. Additionally, a business plan and exploitation strategy will be developed, targeting a spinoff creation to commercialize the technology.
Funding and Support
The support of the EIC Transition grant is crucial to conduct preclinical studies, optimize the SPCCT system, and develop a comprehensive regulatory strategy.
Conclusion
By addressing critical healthcare needs and aligning with EU strategic autonomy in MedTech, ScanNanoTreat will radically improve cancer care and contribute to the sustainability of European healthcare systems.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.911 |
| Totale projectbegroting | € 2.499.911 |
Tijdlijn
| Startdatum | 1-6-2025 |
| Einddatum | 31-5-2028 |
| Subsidiejaar | 2025 |
Partners & Locaties
Projectpartners
- UNIVERSITE LYON 1 CLAUDE BERNARDpenvoerder
- UNIVERSITEIT MAASTRICHT
- GUERBET SA
- PHILIPS FRANCE COMMERCIAL
- INLECOM COMMERCIAL PATHWAYS COMPANYLIMITED BY GUARANTEE
- LYON INGENIERIE PROJETS
Land(en)
Vergelijkbare projecten binnen EIC Transition
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Very High Energy Electrons Beam for RadiotherapyeBeam4Therapy aims to revolutionize cancer treatment by developing compact, cost-effective VHEE radiotherapy using laser plasma accelerators to improve patient outcomes and reduce side effects. | EIC Transition | € 2.477.043 | 2022 | Details |
High-throughput hyperspectral imaging across the VIS-SWIR spectrum in a single deviceThe HYPERIA project aims to develop a novel hyperspectral imaging camera using Fourier Transform interferometry for enhanced sensitivity and wavelength range, targeting applications in food safety and waste separation. | EIC Transition | € 1.500.000 | 2022 | Details |
Targeting cardiac fibrosis with next generation RNA therapeuticsFIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness. | EIC Transition | € 2.499.482 | 2022 | Details |
Laser digital transfer of 2D materials enabled photonics: from the lab 2 the fabThe L2D2 project aims to develop a green, scalable technology for growing and integrating high-quality graphene and 2D materials onto silicon substrates, enabling industrial applications and commercialization. | EIC Transition | € 2.499.975 | 2022 | Details |
Very High Energy Electrons Beam for Radiotherapy
eBeam4Therapy aims to revolutionize cancer treatment by developing compact, cost-effective VHEE radiotherapy using laser plasma accelerators to improve patient outcomes and reduce side effects.
High-throughput hyperspectral imaging across the VIS-SWIR spectrum in a single device
The HYPERIA project aims to develop a novel hyperspectral imaging camera using Fourier Transform interferometry for enhanced sensitivity and wavelength range, targeting applications in food safety and waste separation.
Targeting cardiac fibrosis with next generation RNA therapeutics
FIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness.
Laser digital transfer of 2D materials enabled photonics: from the lab 2 the fab
The L2D2 project aims to develop a green, scalable technology for growing and integrating high-quality graphene and 2D materials onto silicon substrates, enabling industrial applications and commercialization.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
2D Material-Based Multiple Oncotherapy Against Metastatic Disease Using a Radically New Computed Tomography ApproachPERSEUS aims to develop a novel nanotechnology-based cancer therapy that activates under CT imaging to treat deep-seated, drug-resistant tumors with minimal side effects. | EIC Pathfinder | € 2.740.675 | 2023 | Details |
Next generation Limited-Angle time-of-flight PET imagerThe PetVision project aims to develop a cost-effective, modular PET imaging device with enhanced sensitivity to improve cancer diagnostics accessibility across various medical settings. | EIC Pathfinder | € 3.374.041 | 2023 | Details |
Nanoscintillators to potentiate brain cancer radiotherapy: from physics to preclinical trialsThis project aims to enhance radiation therapy for glioblastoma by studying nanoscintillators' effects on tumor tissues, improving treatment efficacy while minimizing damage to healthy cells. | ERC STG | € 1.948.125 | 2024 | Details |
Development of innovative proton and neutron therapies with high cancer specificity by 'hijacking' the intracellular chemistry of haem biosynthesis.NuCapCure aims to develop novel cancer treatments for glioblastoma by utilizing custom-made drugs through biosynthesis to enhance proton and neutron therapies for better targeting and efficacy. | EIC Pathfinder | € 5.972.875 | 2024 | Details |
2D Material-Based Multiple Oncotherapy Against Metastatic Disease Using a Radically New Computed Tomography Approach
PERSEUS aims to develop a novel nanotechnology-based cancer therapy that activates under CT imaging to treat deep-seated, drug-resistant tumors with minimal side effects.
Next generation Limited-Angle time-of-flight PET imager
The PetVision project aims to develop a cost-effective, modular PET imaging device with enhanced sensitivity to improve cancer diagnostics accessibility across various medical settings.
Nanoscintillators to potentiate brain cancer radiotherapy: from physics to preclinical trials
This project aims to enhance radiation therapy for glioblastoma by studying nanoscintillators' effects on tumor tissues, improving treatment efficacy while minimizing damage to healthy cells.
Development of innovative proton and neutron therapies with high cancer specificity by 'hijacking' the intracellular chemistry of haem biosynthesis.
NuCapCure aims to develop novel cancer treatments for glioblastoma by utilizing custom-made drugs through biosynthesis to enhance proton and neutron therapies for better targeting and efficacy.